会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Monocyte-origin multipotent cell MOMC
    • 单核细胞来源的多能细胞MOMC
    • US07795018B2
    • 2010-09-14
    • US10549707
    • 2004-03-18
    • Masataka KuwanaHiroaki Kodama
    • Masataka KuwanaHiroaki Kodama
    • C12N5/077C12N5/0786C12N5/0789C12N5/0793G01N33/00G01N33/53
    • C12N5/0657A61K35/12A61K2035/124C12N5/0619C12N5/0623C12N5/0647C12N5/0662C12N5/069C12N2501/585C12N2506/115
    • The present invention is to provide a multipotent cell wherein the sufficient amount necessary can be stably and conveniently supplied with a minimum invasion, that will not cause rejection at the time of cell transplantation, that has a potential to differentiate into various cells such as mesenchymal cells including bone, cartilage, skeletal muscle and fat, endothelial cells, myocardial cells, neurons, mesenchymal cells, myocardial cells, endothelial cells, neurons induced to differentiate from the multipotent cell, and a therapeutic agent/treating method comprising these as active ingredient. Peripheral blood mononuclear cells (PMBC) are cultured on fibronectin-coated plastic plates for 7 to 10 days. The generating cell population with a fibroblast-like morphology is derived from circulating CD14+ monocyte, with a unique phenotype of CD14+CD45+CD34+ type I collagen+. These cells have a potential to differentiate into mesenchymal cells including bone, cartilage, skeletal muscle and fat, endothelial cells, myocardial cells, and neurons under particular culture conditions.
    • 本发明提供一种多潜能细胞,其中必需的足够量可稳定且方便地以最小的侵入进行,其不会在细胞移植时引起排斥,其可能分化成各种细胞如间充质细胞 包括骨,软骨,骨骼肌和脂肪,内皮细胞,心肌细胞,神经元,间充质细胞,心肌细胞,内皮细胞,诱导与多潜能细胞分化的神经元,以及包含它们作为活性成分的治疗剂/治疗方法。 将外周血单核细胞(PMBC)在纤连蛋白涂覆的塑料板上培养7至10天。 具有成纤维细胞样形态的产生细胞群源自循环CD14 +单核细胞,具有CD14 + CD45 + CD34 + I型胶原+的独特表型。 这些细胞具有在特定培养条件下分化成包括骨,软骨,骨骼肌和脂肪,内皮细胞,心肌细胞和神经元在内的间充质细胞的潜力。
    • 3. 发明申请
    • Monocyte-origin multipotent cell momc
    • 单核细胞来源多能细胞
    • US20060171928A1
    • 2006-08-03
    • US10549707
    • 2004-03-18
    • Masataka KuwanaHiroaki Kodama
    • Masataka KuwanaHiroaki Kodama
    • C12N5/08A61K35/30
    • C12N5/0657A61K35/12A61K2035/124C12N5/0619C12N5/0623C12N5/0647C12N5/0662C12N5/069C12N2501/585C12N2506/115
    • The present invention is to provide a multipotent cell wherein the sufficient amount necessary can be stably and conveniently supplied with a minimum invasion, that will not cause rejection at the time of cell transplantation, that has a potential to differentiate into various cells such as mesenchymal cells including bone, cartilage, skeletal muscle and fat, endothelial cells, myocardial cells, neurons, mesenchymal cells, myocardial cells, endothelial cells, neurons induced to differentiate from the multipotent cell, and a therapeutic agent/treating method comprising these as active ingredient. Peripheral blood mononuclear cells (PMBC) are cultured on fibronectin-coated plastic plates for 7 to 10 days. The generating cell population with a fibroblast-like morphology is derived from circulating CD14+ monocyte, with a unique phenotype of CD14+CD45+CD34+ type I collagen+. These cells have a potential to differentiate into mesenchymal cells including bone, cartilage, skeletal muscle and fat, endothelial cells, myocardial cells, and neurons under particular culture conditions.
    • 本发明提供一种多潜能细胞,其中必需的足够量可稳定且方便地以最小的侵入进行,其不会在细胞移植时引起排斥,其可能分化成各种细胞如间充质细胞 包括骨,软骨,骨骼肌和脂肪,内皮细胞,心肌细胞,神经元,间充质细胞,心肌细胞,内皮细胞,诱导与多潜能细胞分化的神经元,以及包含它们作为活性成分的治疗剂/治疗方法。 将外周血单核细胞(PMBC)在纤连蛋白涂覆的塑料板上培养7至10天。 具有成纤维细胞样形态的产生细胞群源自循环CD14 +单核细胞,具有独特的CD14 + CD45 + CD34 + SUP + + I型胶原蛋白+ 。 这些细胞具有在特定培养条件下分化成包括骨,软骨,骨骼肌和脂肪,内皮细胞,心肌细胞和神经元在内的间充质细胞的潜力。
    • 4. 发明申请
    • Diagnostic for scleroderma
    • 诊断为硬皮病
    • US20050042652A1
    • 2005-02-24
    • US10877683
    • 2004-06-25
    • Masataka Kuwana
    • Masataka Kuwana
    • G01N33/53A61K38/00A61K39/395A61P17/00C07K14/47C07K16/40C07K16/42C12P21/08G01N33/68C12Q1/68
    • C07K16/40C07K2317/21G01N33/686G01N33/6881G01N2333/9125
    • As anti-RNA polymerase (RNAP) antibodies are detected with high frequency in patients suffering from cutaneous scleroderma where skin sclerosis progresses rapidly, supervenes scleroderma renal crisis at a high rate, and associates with clinical entities whose prognoses are extremely bad, it is intended to provide a convenient method of detecting an anti-RNAP antibodies, which is extremely useful in diagnosing and classifying clinical entities of scleroderma, and predicting organ failure, in particular scleroderma renal crisis. In order to identify an epitope recognized commonly by anti-RNAP antibodies, the full length of RPC62 and a partial fragment of RPC155, that are 2 subunits of 62-kDa and 155-kDa of RNAP III, are expressed in Escherichia coli as recombinant proteins, and the reactivities to sera positive and negative to anti-RNAP antibody from patients suffering from scleroderma are examined by immunoblotting method to confirm that an epitope recognized by anti-RNAP antibodies in the sera from the patients suffering from scleroderma exists in 891 to 1020 amino acid residues of RPC155.
    • 由于皮肤硬化症进展迅速的皮肤硬皮病患者高反应性检测到抗RNA聚合酶(RNAP)抗体,因此以高速率超过硬皮病肾脏危象,并与预后极差的临床实体相关联, 提供了一种方便的检测抗RNAP抗体的方法,该方法在诊断和分类硬皮病临床实体以及预防器官衰竭方面非常有用,特别是硬皮病肾脏危象。 为了鉴定抗-RNAP抗体通常识别的表位,RPC62的全长和RPC155的部分片段,其是62-kDa和155-kDa的RNAP III的2个亚基,在大肠杆菌中表达为重组蛋白 ,并通过免疫印迹法检测来自硬皮病患者对抗RNAP抗体的阳性和阴性对血清的反应性,以确认来自硬皮病患者血清中抗-RNAP抗体识别的表位存在于891至1020个氨基 RPC155的酸残基。
    • 5. 发明授权
    • Diagnostic for scleroderma
    • 诊断为硬皮病
    • US07262062B2
    • 2007-08-28
    • US10877683
    • 2004-06-25
    • Masataka Kuwana
    • Masataka Kuwana
    • G01N33/564G01N33/53C07K14/435C07K16/18C07K16/42
    • C07K16/40C07K2317/21G01N33/686G01N33/6881G01N2333/9125
    • As anti-RNA polymerase (RNAP) antibodies are detected with high frequency in patients suffering from cutaneous scleroderma where skin sclerosis progresses rapidly, supervenes scleroderma renal crisis at a high rate, and associates with clinical entities whose prognoses are extremely bad, it is intended to provide a convenient method of detecting an anti-RNAP antibodies, which is extremely useful in diagnosing and classifying clinical entities of scleroderma, and predicting organ failure, in particular scleroderma renal crisis. In order to identify an epitope recognized commonly by anti-RNAP antibodies, the full length of RPC62 and a partial fragment of RPC155, that are 2 subunits of 62-kDa and 155-kDa of RNAP III, are expressed in Escherichia coli as recombinant proteins, and the reactivities to sera positive and negative to anti-RNAP antibody from patients suffering from scleroderma are examined by immunoblotting method to confirm that an epitope recognized by anti-RNAP antibodies in the sera from the patients suffering from scleroderma exists in 891 to 1020 amino acid residues of RPC155.
    • 由于皮肤硬化症进展迅速的皮肤硬皮病患者高反应性检测到抗RNA聚合酶(RNAP)抗体,因此以高速率超过硬皮病肾脏危象,并与预后极差的临床实体相关联, 提供了一种方便的检测抗RNAP抗体的方法,该方法在诊断和分类硬皮病临床实体以及预防器官衰竭方面非常有用,特别是硬皮病肾脏危象。 为了鉴定抗-RNAP抗体通常识别的表位,RPC62的全长和RPC155的部分片段,其是62-kDa和155-kDa的RNAP III的2个亚基,在大肠杆菌中表达为重组蛋白 ,并通过免疫印迹法检测来自硬皮病患者对抗RNAP抗体的阳性和阴性对血清的反应性,以确认来自硬皮病患者血清中抗-RNAP抗体识别的表位存在于891至1020个氨基 RPC155的酸残基。